Abstract
Alzheimers disease imposes a significant public health burden that will only worsen as the population ages. Thus, there is considerable motivation to develop effective strategies to treat, or more ideally, prevent the disease. Epidemiologic evidence has suggested that non-steroidal anti-inflammatory drugs (or NSAIDs) may be neuro-protective. However, this evidence is controversial. Observational studies in humans have found that the use of NSAIDs is associated with a lower risk of developing Alzheimers disease. By contrast, randomized trials have reported that NSAIDs are not effective in treating patients with clinically established disease nor in preventing the onset of dementia among those who are cognitively normal or have mild cognitive impairment. In this article, we review the existing epidemiologic evidence on the relationship between NSAIDs and Alzheimers disease and discuss several hypotheses to explain the divergent findings.
CNS & Neurological Disorders - Drug Targets
Title: Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence
Volume: 9 Issue: 2
Author(s): C.A. Szekely and P.P. Zandi
Affiliation:
Abstract: Alzheimers disease imposes a significant public health burden that will only worsen as the population ages. Thus, there is considerable motivation to develop effective strategies to treat, or more ideally, prevent the disease. Epidemiologic evidence has suggested that non-steroidal anti-inflammatory drugs (or NSAIDs) may be neuro-protective. However, this evidence is controversial. Observational studies in humans have found that the use of NSAIDs is associated with a lower risk of developing Alzheimers disease. By contrast, randomized trials have reported that NSAIDs are not effective in treating patients with clinically established disease nor in preventing the onset of dementia among those who are cognitively normal or have mild cognitive impairment. In this article, we review the existing epidemiologic evidence on the relationship between NSAIDs and Alzheimers disease and discuss several hypotheses to explain the divergent findings.
Export Options
About this article
Cite this article as:
Szekely C.A. and Zandi P.P., Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence, CNS & Neurological Disorders - Drug Targets 2010; 9 (2) . https://dx.doi.org/10.2174/187152710791012026
DOI https://dx.doi.org/10.2174/187152710791012026 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effects of Combined Omega-3 Fatty Acids and Valproic Acid Supplementation on Symptoms of Borderline Personality Disorder: A Pilot Study
Current Psychopharmacology Chinese Herbs for Dementia Diseases
Mini-Reviews in Medicinal Chemistry Acceptability and Results of Dementia Screening Among Older Adults in the United States
Current Alzheimer Research Editorial
Current Medical Imaging The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews Biomarkers of Senescence during Aging as Possible Warnings to Use Preventive Measures
Current Medicinal Chemistry NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in AβPPswe/PS-1 Mice of Different Ages
Current Alzheimer Research Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design Benefits of Caloric Restriction on Brain Aging and Related Pathological States: Understanding Mechanisms to Devise Novel Therapies
Current Medicinal Chemistry An Increase in Aβ42 in the Prefrontal Cortex is Associated with a Reversal-Learning Impairment in Alzheimers Disease Model Tg2576 APPsw Mice
Current Alzheimer Research Diagnostic and Prognostic Potential of Retinal Biomarkers in Early On-Set Alzheimer’s Disease
Current Alzheimer Research Association Constants of Pyridine and Piperidine Alkaloids to Amyloid ß Peptide Determined by Electrochemical Impedance Spectroscopy
Current Alzheimer Research Alzheimer’s Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Current Alzheimer Research Alzheimer´s Disease and Oxidative Stress: A Review
Current Medicinal Chemistry Pharmacotherapy of Persons with Dementia in Long-term Care in Australia: A Descriptive Audit of Central Nervous System Medications
Current Drug Safety Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Classic β-Amyloid Deposits Cluster Around Large Diameter Blood Vessels Rather than Capillaries in Sporadic Alzheimers Disease
Current Neurovascular Research From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Can Diet and Physical Activity Limit Alzheimer's Disease Risk?
Current Alzheimer Research